Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

FIBROSIS

Collagen-targeted MRI contrast agent for liver fibrosis detection

A novel MRI gadolinium-based contrast agent designed to bind with collagen, a key component in liver fibrosis progression, provides direct quantification of collagen deposition in several preclinical liver disease models. This tool could have large implications in clinical diagnosis and drug trials.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Staging fibrosis with magnetic resonance imaging.

References

  1. 1.

    Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69, 896–904 (2018).

    Article  Google Scholar 

  2. 2.

    Salarian, M. et al. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nat Commun 10, 4777 (2019).

    Article  Google Scholar 

  3. 3.

    Tapper, E. B. & Lok, A. S. F. Use of liver imaging and biopsy in clinical practice. N. Engl. J. Med. 377, 756–768 (2017).

    Article  Google Scholar 

  4. 4.

    Zarski, J. P. et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J. Hepatol. 56, 55–62 (2012).

    Article  Google Scholar 

  5. 5.

    Kennedy, P. et al. Quantitative elastography methods in liver disease: current evidence and future directions. Radiology 286, 738–763 (2018).

    Article  Google Scholar 

  6. 6.

    Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425–456 (2011).

    CAS  Article  Google Scholar 

  7. 7.

    Farrar, C. T. et al. CM-101: Type I collagen-targeted MR imaging probe for detection of liver fibrosis. Radiology 287, 581–589 (2018).

    Article  Google Scholar 

  8. 8.

    Xue, S. H. et al. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc. Natl Acad. Sci. USA 112, 6607–6612 (2015).

    CAS  Article  Google Scholar 

  9. 9.

    Ellis, E. L. & Mann, D. A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 56, 1171–1180 (2012).

    Article  Google Scholar 

  10. 10.

    Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 53, 362–376 (2018).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Bachir Taouli.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kennedy, P., Taouli, B. Collagen-targeted MRI contrast agent for liver fibrosis detection. Nat Rev Gastroenterol Hepatol 17, 201–202 (2020). https://doi.org/10.1038/s41575-020-0266-z

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing